Press Releases
Keyword Search
 
2015 | 2014
DateTitle 
05/27/15Collegium to Present at the Jefferies 2015 Global Healthcare Conference
CANTON, Mass., May 27, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company's Chairman and CEO, Michael Heffernan, will present at the Jefferies 2015 Healthcare Conference in New York City. The presentation is scheduled for Monday, June 1, 2015 at 1:30pm Eastern Time. About Collegium Pharmaceutical, Inc. Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETE... 
Printer Friendly Version
05/12/15Collegium Pharmaceutical Announces Closing of Its Initial Public Offering and Exercise in Full of Option to Purchase Additional Shares
CANTON, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the closing of its initial public offering of 6,670,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissions, including shares issued upon the exercise of the underwriters' option to purchase additional shares, resulting in gross proceeds of $80.0 million. The company's shares began trading on The NASDAQ Global Select Marke... 
Printer Friendly Version
05/07/15Collegium Pharmaceutical Announces Pricing of Its Initial Public Offering
CANTON, Mass., May 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., (Nasdaq:COLL) today announced the pricing of its initial public offering of 5,800,000 shares of its common stock at a price to the public of $12.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Collegium. In addition, Collegium has granted the underwriters a 30-day option to purchase from Collegium up to an additional 870,000 shares of common stock. Colle... 
Printer Friendly Version
03/17/15Collegium Pharmaceutical to Present Xtampza ER™ Pivotal Phase III Data at the 2015 American Academy of Pain Medicine Annual Meeting
Canton, MA – March 17, 2015 – Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company’s completed Phase III clinical trial that evaluated the efficacy and safety of its lead drug candidate, Xtampza ER™, an abuse-deterrent, extended-release analgesic for chronic pain. The poster will be presented at the American Academy of Pain Medicine’s (AAPM) 31st Annual Meeting, being heldon March 19-22, 2015 at the Gaylord National Resort and Convention Center, National Harbor, Ma... 
Printer Friendly Version
03/10/15Collegium Pharmaceutical Raises $50 Million Financing to Support Commercial Development of its Lead Abuse-Deterrent Product Candidate
Funding follows NDA acceptance of Xtampza ER™ in February 2015Canton, MA – March 10, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today announced that it has raised a $50 million financing. Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER (oxycodone extended-release capsul... 
Printer Friendly Version
02/26/15Collegium Pharmaceutical Announces Notice of Allowance for U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Xtampza ER™ utilizes the DETERx Technology PlatformCanton, MA – February 26, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced that Application No. 13/551,455, an application relating its DETERx technology platform, was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The patent contains claims that p... 
Printer Friendly Version
02/12/15Collegium Pharmaceutical Announces FDA Acceptance for Filing of NDA for Xtampza ER™ (oxycodone extended-release capsules), an Abuse-Deterrent Analgesic for Chronic Pain
Canton, MA – February 12, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for Xtampza ER, its novel, abuse-deterrent, extended-release oxycodone formulation for the treatment of chronic pain. Xtampza ER is Collegium... 
Printer Friendly Version
02/09/15Collegium Pharmaceutical Appoints Chief Financial Officer and New Member to Its Board of Directors
Management team significantly strengthened by adding financial expertiseCanton, MA – February 9, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent treatments for chronic pain and other diseases, announced today the appointments of Paul Brannelly as Executive Vice President and Chief Financial Officer and Garen Bohlin to its Board of Directors, effective immediately.“Adding Paul to Collegium’s m... 
Printer Friendly Version
01/15/15“Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain with Dysphagia (CPD),” Published in Pain Practice
Clinical study demonstrates that the Xtampza ER™ ER (oxycodone extended-release) drug release profile is maintained when sprinkled onto foodCanton, MA – January 15, 2015 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of “Evaluation of an Extended-Release, Abuse-Deterrent, Microsphere-in-Capsule Analgesic for the Management of Patients with Chronic Pain With Dysphagia (CPD),... 
Printer Friendly Version